|
IUdR/BUdR cell cycle labelling Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on IUdR/BUdR cell cycle labelling conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. IUdR/BUdR cell cycle labelling Clinical research trials and IUdR/BUdR cell cycle labelling healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like IUdR/BUdR cell cycle labelling. IUdR/BUdR cell cycle labelling Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a IUdR/BUdR cell cycle labelling clinical trial. Human subjects often obtain the finest healthcare possible for their IUdR/BUdR cell cycle labelling condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > IUdR/BUdR cell cycle labelling IUdR/BUdR cell cycle labelling
IUdR/BUdR cell cycle labelling
For Condition: Hematologic Malignancies
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.
Details: Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.
Eligibility:
Study Type: Interventional, Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Histologic proof of one of: - AML, ALL, or AUL - MDS or CMML - CML - OR undergoing bone marrow transplantation. Participants should be: - off therapy for at least two weeks - At least 18 years old or older - Using adequate contraception if of child-bearing capability.
Total Enrollment: 180
Location and Contact Information:
Overall Study Official:
MichaelAndreeff, Study Chair, U. T. M. D. Anderson Cancer Center
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: DM91-102;
Study Start Date: October 1991
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042250
Other Hematologic Malignancies Studies:
1. Stem Cell Transplant for Patients with Hematologic Malignancy Using Family Donors and Conditioning with Campath-1H
2. Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
3. IUdR/BUdR cell cycle labelling
Related Studies:
Other Hematologic Malignancies Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
IUdR/BUdR cell cycle labelling
|
|
|
|
|
|
|
|